# A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

> **NCT05188417** · PHASE2 · UNKNOWN · sponsor: **GrandPharma (China) Co., Ltd.** · enrollment: 266 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Tirofiban 0.05 MG/ML
- **DRUG:** 0.9% sodium chloride solution

## Key facts

- **NCT ID:** NCT05188417
- **Lead sponsor:** GrandPharma (China) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-09
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188417, "A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05188417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*